ArticleInternational journal of clinical and experimental pathology2015
Elevated JMJD1A is a novel predictor for prognosis and a potential therapeutic target for gastric cancer.
Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 29 citations in OpenAlex.
- KDM3A Modulates Trastuzumab Resistance in HER2- Positive Breast Cancer Cells via the PI3K/AKT/ERK Pathway.Biochemical genetics · 2026Article
- The JMJD family histone demethylases: structure, mechanism of action, diseases and therapeutic targets.Molecular biomedicine · 2026Review
- KDM3A, a Novel Blood-Based Biomarker in Colorectal Carcinogenesis.Balkan journal of medical genetics : BJMG · 2023Article
- Histone Demethylase KDM3 (JMJD1) in Transcriptional Regulation and Cancer Progression.Advances in experimental medicine and biology · 2023Article
- JMJD family proteins in cancer and inflammation.Signal transduction and targeted therapy · 2022Review
- Histone demethylase JMJD1A in cancer progression and therapeutic resistance.Molecular carcinogenesis · 2022Article
- Histone demethylase Jumonji domain-containing 1A inhibits proliferation and progression of gastric cancer by upregulating runt-related transcription factor 3.Cancer science · 2020Article
- Epigenetic Mechanisms in Gastric Cancer: Potential New Therapeutic Opportunities.International journal of molecular sciences · 2020Review
- MAP Kinases Pathways in Gastric Cancer.International journal of molecular sciences · 2020Review
- The histone demethylase JMJD2B regulates endothelial-to-mesenchymal transition.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Inhibition of G9a promoted 5-fluorouracil (5-FU) induced gastric cancer cell apoptosisRSC advances · 2019Article
- H3K9 methyltransferases and demethylases control lung tumor-propagating cells and lung cancer progression.Nature communications · 2018Article
- Long non-coding RNAs involved in metastasis of gastric cancer.World journal of gastroenterology · 2018Review
- KDM3A is not associated with metastasis and prognosis of breast cancer.Oncology letters · 2018Article
- Hypoxia-inducible KDM3A addiction in multiple myeloma.Blood advances · 2018Article
- JMJD1A, H3K9me1, H3K9me2 and ADM expression as prognostic markers in oral and oropharyngeal squamous cell carcinoma.PloS one · 2018Article
- The histone demethylase Kdm3a is required for normal epithelial proliferation, ductal elongation and tumor growth in the mouse mammary gland.Oncotarget · 2017Article
- The histone demethylase KDM3A, and its downstream target MCAM, promote Ewing Sarcoma cell migration and metastasis.Oncogene · 2017Article
- Integrated Analysis of LncRNA-mRNA Co-Expression Profiles in Patients with Moyamoya Disease.Scientific reports · 2017Article
- The Emerging Role of Histone Demethylases in Renal Cell Carcinoma.Journal of kidney cancer and VHL · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Jumonji domain-containing protein 1A (JMJD1A) play a key role in the development and progression of several malignancies. The present study investigated the expression and clinical significance of JMJD1A in gastric cancer. JMJD1A was found to be upregulated in gastric cancer tissues and cell lines. Furthermore, the upregulated expression of JMJD1A was significantly correlated with the results of the invasion depth (P=0.006), lymph node metastatic status (P<0.001), and TNM stage (P<0.001). JMJD1A was also shown to be an independent prognostic predictor of overall survival (HR3.988; 95% CI 1.948-8.167; P<0.001) for patients with gastric cancer. In addition, in vitro experiment revealed that knockdown of JMJD1A expression inhibited the gastric cancer cell proliferation, and further study suggested that JMJD1A knockdown suppressed MAPK pathway via transcriptional downregulation the expression of long noncoding RNA MALAT1. Therefore, we speculated that JMJD1A-MALAT1-MAPK signaling might participate in the JMJD1A-induced cell proliferation of gastric cancer. Collectively, our data demonstrate for the first time that JMJD1A gene has an important regulatory role in gastric carcinogenesis, and could function as a novel prognostic indicator and a potential therapeutic target for gastric cancer.
Indexed as
Identifiers
26617828PMC4637643W2188150684What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.